Skip to main content
. Author manuscript; available in PMC: 2021 Nov 2.
Published in final edited form as: Mol Pharm. 2020 Oct 6;17(11):4201–4211. doi: 10.1021/acs.molpharmaceut.0c00665

Figure 3.

Figure 3.

Clinical scores of EAE mice treated in vivo with (A) free PLP139–151 and (B) 4-arm PLP139–151. Treatments were administered subcutaneously on days 4, 7, and 10 with 40 mg/mL mannitol as vehicle. All doses were based on 200 nmol PLP139–151 basis. N=6 for all groups. Data is presented as mean ± SD.